---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-003491"
form_type: "8-K"
ticker: "BDSX"
cik: "0001439725"
company_name: "BIODESIX INC"
filed_at: "2022-03-14T23:59:59+00:00"
generated_at: "2026-06-26T23:10:00.531750+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Biodesix reports FY2021 revenue $54.5M; core lung diagnostic up 49% YoY to $18.7M; net loss $43.2M

## Summary
- Q4 total revenue $7.2M; core lung diagnostic revenue $5.4M (+48% YoY); BioPharma services $1.4M (-29% YoY).
- FY2021 total revenue $54.5M; core lung diagnostic $18.7M (+49% YoY); COVID-19 testing revenue $30.2M (+7% YoY).
- Q4 gross margin 65% vs 46% YoY driven by mix shift to higher-margin lung diagnostics; operating expenses $16.4M.
- Net loss Q4 $13.3M (increase of 193% YoY); FY2021 net loss $43.2M (increase 38% YoY).
- Guides FY2022 total revenue $37.5M-$39.5M; cash $32.7M after $20M debt prepayment and $15.7M equity raise.

## SEC filing metadata
- accession: 0000950170-22-003491
- form_type: 8-K
- ticker: BDSX
- cik: 0001439725
- company_name: BIODESIX INC
- filed_at: 2022-03-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439725/000095017022003491/0000950170-22-003491-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439725/000095017022003491/bdsx-20220314.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-003491
- JSON: https://secwatch.observer/filing/0000950170-22-003491.json
- Plain text: https://secwatch.observer/filing/0000950170-22-003491.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.